Bradycor bradykinin antagonist data

CRTQ released positive data from its pilot Phase II trial in 20 patients in South Africa. Patients in the single-blind, placebo-controlled study who received 3 µg/kg/minute of Bradycor for seven days showed a statistically significant 68 percent relative reduction in peak intracranial pressure (ICP) compared to patients on placebo.

There also was a statistically significant reduction in deterioration of neurological function as measured by the Glasgow Coma Score, which is used to assess brain function in head injury patients. ...